Fidi Koppel
Impact in
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
-
- Antibiotic Use and Resistance
Papers in
-
- Antibiotic Resistance in Bacteria 12
-
- Antibiotic Use and Resistance 5
- Co-authors
- Mical Paul (4 shared papers)Oren Zusman (1 shared paper)Sergey Altunin (1 shared paper)Yael Dishon Benattar (1 shared paper)Habip Gedık (1 shared paper)Adi Turjeman (3 shared papers)Dafna Yahav (3 shared papers)Erica Franceschini (2 shared papers)
In The Last Decade
Fidi Koppel
18 papers receiving 1.4k citations
Fidi Koppel's Hit Papers
Peers
Comparison fields: 5 of 61
- Molecular Medicine 883
- Applied Microbiology and Biotechnology 272
- Pharmacology 202
- Critical Care and Intensive Care Medicine 48
- Clinical Biochemistry 48
Countries citing papers authored by Fidi Koppel
This map shows the geographic impact of Fidi Koppel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fidi Koppel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fidi Koppel more than expected).
Fields of papers citing papers by Fidi Koppel
This network shows the impact of papers produced by Fidi Koppel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fidi Koppel. The network helps show where Fidi Koppel may publish in the future.
Co-authors
The 25 scholars most cited alongside Fidi Koppel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial Hit paper breakdown → | 2018 | 513 |
| 2 | Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial Hit paper breakdown → | 2018 | 339 |
| 3 | 2016 | 147 | |
| 4 | 2018 | 102 | |
| 5 | 2020 | 64 | |
| 6 | 2022 | 42 | |
| 7 | 2016 | 39 | |
| 8 | 2018 | 37 | |
| 9 | 2023 | 24 | |
| 10 | 2021 | 21 | |
| 11 | 2022 | 18 | |
| 12 | 2019 | 17 | |
| 13 | 1992 | 9 | |
| 14 | 2021 | 9 | |
| 15 | 2021 | 3 | |
| 16 | 2021 | 2 | |
| 17 | 2022 | 2 | |
| 18 | 2025 | 1 |
About Fidi Koppel
Fidi Koppel is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Epidemiology, Pharmacology and Geriatrics and Gerontology, having authored 18 papers that have together received 1.4k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (12 papers), Antibiotic Use and Resistance (5 papers), Sepsis Diagnosis and Treatment (4 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers), Urinary Tract Infections Management (1 paper), Frailty in Older Adults (1 paper), Ethics in Clinical Research (1 paper) and Health Systems, Economic Evaluations, Quality of Life (1 paper). The work is most often cited by research in Molecular Medicine (883 citations), Applied Microbiology and Biotechnology (272 citations), Pharmacology (202 citations), Critical Care and Intensive Care Medicine (48 citations) and Clinical Biochemistry (48 citations). Fidi Koppel has collaborated with scholars based in Israel, Italy and Greece. Frequent co-authors include Mical Paul, Oren Zusman, Sergey Altunin, Yael Dishon Benattar, Habip Gedık, Adi Turjeman, Dafna Yahav, Erica Franceschini, Leonard Leibovici and José Molina. Their work appears in journals such as Clinical Infectious Diseases, Clinical Microbiology and Infection, BMJ Open, EClinicalMedicine and Water Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.